Literature DB >> 19703887

Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis.

Philip M Farrell1, Jannette Collins, Lynn S Broderick, Michael J Rock, Zhanhai Li, Michael R Kosorok, Anita Laxova, William M Gershan, Alan S Brody.   

Abstract

PURPOSE: To correlate the severity of bronchiectasis in children with cystic fibrosis with clinical and microbiologic variables in order to clarify risk factors for the development of irreversible lung disease.
MATERIALS AND METHODS: After institutional review board approval and parental informed consents were obtained, a HIPAA-compliant longitudinal epidemiologic evaluation was performed in patients with cystic fibrosis who were enrolled in the Wisconsin trial of newborn screening from 1985 to 2009. Thin-section chest computed tomography (CT) was used in a prospective cross-sectional design to study patients ranging in age from 6.6 to 17.6 years (mean, 11.5 years). Thin-section CT scores were determined objectively on coded images by multiple raters in a standardized fashion. Microbiologic data were obtained by means of culture of respiratory secretions by using methods for differentiation of Pseudomonas aeruginosa (PA) as either nonmucoid or mucoid.
RESULTS: Eighty-three percent of patients (68 of 82) showed bronchiectasis of varying severity. Of 12 potential risk factors, only respiratory infection with mucoid PA correlated significantly with bronchiectasis (P = .041).
CONCLUSION: The severity of bronchiectasis in children with cystic fibrosis is significantly related to respiratory infection with mucoid PA; attempts to prevent bronchiectasis should include reducing exposure to and early eradication of PA.

Entities:  

Mesh:

Year:  2009        PMID: 19703887      PMCID: PMC2753783          DOI: 10.1148/radiol.2522081882

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  54 in total

1.  A comparison of serial computed tomography and functional change in bronchiectasis.

Authors:  R E Sheehan; A U Wells; S J Copley; S R Desai; S J Howling; P J Cole; R Wilson; D M Hansell
Journal:  Eur Respir J       Date:  2002-09       Impact factor: 16.671

2.  Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.

Authors:  Ronald L Gibson; Julia Emerson; Sharon McNamara; Jane L Burns; Margaret Rosenfeld; Ann Yunker; Nicole Hamblett; Frank Accurso; Mark Dovey; Peter Hiatt; Michael W Konstan; Richard Moss; George Retsch-Bogart; Jeffrey Wagener; David Waltz; Robert Wilmott; Pamela L Zeitlin; Bonnie Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2002-12-12       Impact factor: 21.405

3.  Predictors of deterioration of lung function in cystic fibrosis.

Authors:  C Schaedel; I de Monestrol; L Hjelte; M Johannesson; R Kornfält; A Lindblad; B Strandvik; L Wahlgren; L Holmberg
Journal:  Pediatr Pulmonol       Date:  2002-06

Review 4.  Pathophysiology and management of pulmonary infections in cystic fibrosis.

Authors:  Ronald L Gibson; Jane L Burns; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2003-10-15       Impact factor: 21.405

5.  Early infection and progression of cystic fibrosis lung disease.

Authors:  Christian Koch
Journal:  Pediatr Pulmonol       Date:  2002-09

6.  Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis.

Authors:  Philip M Farrell; Zhanhai Li; Michael R Kosorok; Anita Laxova; Christopher G Green; Jannette Collins; Hui-Chuan Lai; Linda M Makholm; Michael J Rock; Mark L Splaingard
Journal:  Pediatr Pulmonol       Date:  2003-09

Review 7.  Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Am J Infect Control       Date:  2003-05       Impact factor: 2.918

8.  Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic.

Authors:  David S Armstrong; Gillian M Nixon; Rosemary Carzino; Andrea Bigham; John B Carlin; Roy M Robins-Browne; Keith Grimwood
Journal:  Am J Respir Crit Care Med       Date:  2002-10-01       Impact factor: 21.405

9.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

Authors:  Julia Emerson; Margaret Rosenfeld; Sharon McNamara; Bonnie Ramsey; Ronald L Gibson
Journal:  Pediatr Pulmonol       Date:  2002-08

10.  Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors.

Authors:  Susan E H West; Lan Zeng; Bee Leng Lee; Michael R Kosorok; Anita Laxova; Michael J Rock; Mark J Splaingard; Philip M Farrell
Journal:  JAMA       Date:  2002-06-12       Impact factor: 157.335

View more
  22 in total

1.  Regional differences in the evolution of lung disease in children with cystic fibrosis.

Authors:  Zhanhai Li; Don B Sanders; Michael J Rock; Michael R Kosorok; Jannette Collins; Christopher G Green; Alan S Brody; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2011-12-07

Review 2.  The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG.

Authors:  David Skurnik; Colette Cywes-Bentley; Gerald B Pier
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Chest computed tomography scores of severity are associated with future lung disease progression in children with cystic fibrosis.

Authors:  Don B Sanders; Zhanhai Li; Alan S Brody; Philip M Farrell
Journal:  Am J Respir Crit Care Med       Date:  2011-10-01       Impact factor: 21.405

5.  Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung.

Authors:  Sankalp Malhotra; Don Hayes; Daniel J Wozniak
Journal:  J Cyst Fibros       Date:  2019-04-26       Impact factor: 5.482

Review 6.  Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface.

Authors:  Sankalp Malhotra; Don Hayes; Daniel J Wozniak
Journal:  Clin Microbiol Rev       Date:  2019-05-29       Impact factor: 26.132

7.  Cystic fibrosis: an-ion transport issue?

Authors:  Gerald Pier; Alice Prince; André Cantin
Journal:  Nat Med       Date:  2011-02       Impact factor: 53.440

8.  Relationships among health-related quality of life, pulmonary health, and newborn screening for cystic fibrosis.

Authors:  Audrey Tluczek; Tara Becker; Anita Laxova; Adam Grieve; Caroline N Racine Gilles; Michael J Rock; William M Gershan; Christopher G Green; Philip M Farrell
Journal:  Chest       Date:  2010-11-24       Impact factor: 9.410

9.  Risk factors for the progression of cystic fibrosis lung disease throughout childhood.

Authors:  Don B Sanders; Zhanhai Li; Anita Laxova; Michael J Rock; Hara Levy; Jannette Collins; Claude Ferec; Philip M Farrell
Journal:  Ann Am Thorac Soc       Date:  2014-01

10.  Quantitative chest computerized tomography and FEV1 equally identify pulmonary exacerbation risk in children with cystic fibrosis.

Authors:  Don B Sanders; Zhanhai Li; Katelyn Parker-McGill; Philip Farrell; Alan S Brody
Journal:  Pediatr Pulmonol       Date:  2018-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.